|
Rheumatoid Arthritis
|
0.480 |
GeneticVariation
|
disease |
BEFREE |
Of the 31 RA-associated risk alleles, a SNP at the PTPRC (also known as CD45) gene locus (rs10919563) was associated with the primary end point, a EULAR good response versus no response (odds ratio [OR] 0.55, P = 0.0001 in the multivariate model).
|
20309874 |
2010 |
|
Rheumatoid Arthritis
|
0.480 |
AlteredExpression
|
disease |
BEFREE |
Rare cells of undefined nature, detected by flow cytometry following CD45(-) enrichment, strongly expressed surface cadherin-11 (estimated 10-50cells/ml of blood) in 5/6 patients with polyarticular established disease versus 1/6 patients with early RA.
|
25173800 |
2014 |
|
Rheumatoid Arthritis
|
0.480 |
Biomarker
|
disease |
BEFREE |
Patients with PSS compared to normal subjects had significantly lower percentages of CD3+ (p less than 0.005) and CD8+ (p less than 0.05) (similar to several patients with rheumatoid arthritis also evaluated), as well as CD45R (p less than 0.05), T+DR+ (p less than 0.05), and NKH-1 (CD56) (p less than 0.0005) cells.
|
2013671 |
1991 |
|
Rheumatoid Arthritis
|
0.480 |
GeneticVariation
|
disease |
BEFREE |
TRAF1/C5 but not PTPRC variants are potential predictors of rheumatoid arthritis response to anti-tumor necrosis factor therapy.
|
25834819 |
2015 |
|
Rheumatoid Arthritis
|
0.480 |
GeneticVariation
|
disease |
BEFREE |
Based on a previously reported association of RA with the PTPRC genetic locus, the present study was undertaken to test established RA susceptibility variants, including PTPRC, in the prediction of response to TNF blockade in a large cohort of patients from the UK.
|
21952740 |
2012 |
|
Rheumatoid Arthritis
|
0.480 |
Biomarker
|
disease |
BEFREE |
In total, 25 single nucleotide polymorphisms were found to be associated with anti-TNF treatment response in RA (19 from genome-wide association studies and 6 from the meta-analyses), and these map to genes involved in T cell function, NFκB and TNF signalling pathways (including CTCN5, TEC, PTPRC, FCGR2A, NFKBIB, FCGR2A, IRAK3).
|
28607508 |
2017 |
|
Rheumatoid Arthritis
|
0.480 |
GeneticVariation
|
disease |
BEFREE |
The most significant result was obtained with rs10919563 in PTPRC, which is a confirmed RA susceptibility locus.
|
25896535 |
2016 |
|
Rheumatoid Arthritis
|
0.480 |
GeneticVariation
|
disease |
BEFREE |
The PTPRC rs10919563 A allele shows a poor response to anti-TNF therapy, and the FCGR2A HH + HR genotype shows a poor response to adalimumab for RA.
|
27074847 |
2016 |
|
Severe Combined Immunodeficiency
|
0.470 |
GeneticVariation
|
disease |
BEFREE |
Mutations in the tyrosine phosphatase CD45 gene in a child with severe combined immunodeficiency disease.
|
10700239 |
2000 |
|
Severe Combined Immunodeficiency
|
0.470 |
Biomarker
|
disease |
BEFREE |
When the 96 h protocol was used in combination with the spleen focus forming virus (SFFV)/murine embryonic stem cell (MESV) hybrid vector SFbeta11-EGFP, high transduction rates for CD45+ (41.0 +/- 5.3%) and CD34+ (38.5 +/- 3.7%) cells prior to transplantation, as well as efficient human cell engraftment in NOD/SCID mice 4 weeks after transplantation (32.4 +/- 3.5%), was detected.
|
17053889 |
2007 |
|
Severe Combined Immunodeficiency
|
0.470 |
AlteredExpression
|
disease |
BEFREE |
We investigated the first SCID patient to be described with minimal cell surface expression of the leukocyte common (CD45) Ag.
|
11145714 |
2001 |
|
Severe Combined Immunodeficiency
|
0.470 |
GeneticVariation
|
disease |
BEFREE |
Lack of CD45 leads to severe combined immunodeficiency, and alterations of CD45 splicing, because of a polymorphism in exon 4, have been associated with altered immune function.
|
12716971 |
2003 |
|
Severe Combined Immunodeficiency
|
0.470 |
Biomarker
|
disease |
BEFREE |
Therefore, introduction of a functional CD45 minigene is sufficient to overcome the principal severe combined immunodeficiency (SCID)-associated defects and represents a potential route to a gene therapy for human CD45-deficent SCID.
|
12393487 |
2003 |
|
Severe Combined Immunodeficiency
|
0.470 |
Biomarker
|
disease |
BEFREE |
CD45-deficient severe combined immunodeficiency caused by uniparental disomy.
|
22689986 |
2012 |
|
Severe Combined Immunodeficiency
|
0.470 |
Biomarker
|
disease |
BEFREE |
CD45 deficiency results in T- and B-lymphocyte dysfunction in the form of severe combined immune deficiency.
|
29366662 |
2018 |
|
Malignant neoplasm of breast
|
0.340 |
Biomarker
|
disease |
BEFREE |
We performed next generation sequencing- and microarray-based gene expression profiling of CD44(+)/CD24(-)/CD45(-) breast CSCs (cancer stem cells) isolated from primary ERα-positive breast cancer.
|
22771536 |
2012 |
|
Malignant neoplasm of breast
|
0.340 |
GeneticVariation
|
disease |
BEFREE |
Early stage breast cancer patients, versus control women, had reduced serum LCA levels, reduced chenodeoxycholic acid to LCA ratio, and reduced abundance of the baiH (7α/β-hydroxysteroid dehydroxylase, the key enzyme in LCA generation) gene in fecal DNA, all suggesting reduced microbial generation of LCA in early breast cancer.
|
29655782 |
2018 |
|
Malignant neoplasm of breast
|
0.340 |
AlteredExpression
|
disease |
BEFREE |
Formalin-fixed, paraffin-embedded breast cancer samples were analysed on tissue microarrays using mIF, which combined phospho-histone H3 (pHH3) expression with cytokeratin (CK) and leukocyte common antigen (CD45) expression to identify tumour and immune cells, respectively.
|
31410680 |
2019 |
|
Malignant neoplasm of breast
|
0.340 |
Biomarker
|
disease |
BEFREE |
CD45-depleted PBMCs from breast cancer patients' blood were used for CTC capturing.
|
30218306 |
2019 |
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.330 |
Biomarker
|
disease |
BEFREE |
Compared to CD45-low patients, CD45-high patients had a lower event-free survival rate (B-cell-precursor acute lymphoblastic leukemia: 72 ± 3% versus 86 ± 1%, P<0.0001; T-cell acute lymphoblastic leukemia: 60 ± 8% versus 78 ± 4%, P=0.02), which was mainly attributable to a higher cumulative relapse incidence (B-cell-precursor acute lymphoblastic leukemia: 22 ± 3% versus 11 ± 1%, P<0.0001; T-cell acute lymphoblastic leukemia: 31 ± 8% versus 11 ± 3%, P=0.003) and kept its significance in multivariate analysis considering sex, age, initial white blood cell count, and minimal residual disease in B-cell-precursor- and T-cell acute lymphoblastic leukemia, and additionally presence of ETV6/RUNX1, MLL/AF4 and BCR/ABL1 rearrangements in B-cell-precursor acute lymphoblastic leukemia (P=0.002 and P=0.025, respectively).
|
23911702 |
2014 |
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.330 |
Biomarker
|
disease |
BEFREE |
Taken together, our data identify a tumor suppressor role for CD45 in T-cell acute lymphoblastic leukemia.
|
22438252 |
2012 |
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
0.330 |
AlteredExpression
|
disease |
BEFREE |
Substantial Mer RNA levels were principally observed in a subset of T-ALL patient samples that expressed B220 (P = 0.004) but lacked surface expression of CD3 (P = 0.02) and CD4 (P = 0.006), a phenotypic profile consistent with immature lymphoblasts.
|
16675557 |
2006 |
|
Hepatitis C
|
0.320 |
Biomarker
|
disease |
BEFREE |
IFN-α treatment following human PBMC transplantation resulted in a significant reduction in serum HCV RNA titers and a higher human CD45-positive mononuclear cell chimerism compared to mice without human PBMC transplantation.
|
28253324 |
2017 |
|
Hepatitis C
|
0.320 |
GeneticVariation
|
disease |
BEFREE |
Altered CD45 expression in C77G carriers influences immune function and outcome of hepatitis C infection.
|
16505159 |
2006 |
|
Psychotic Disorders
|
0.310 |
Biomarker
|
group |
BEFREE |
Furthermore, in the SG, the number of circulating Lin(-)/CD45(-)/CD34(+) VSELs and the S1P plasma level are the best predictors of risk and are proposed as novel markers for the first "schizophrenic" episode of psychosis.
|
24246416 |
2014 |